[Allogeneic hematopoietic cell transplantation for myelofibrosis: current status and future challenges].

ABSTRACT

Remarkable progress has been made in the field of myelofibrosis recently. Along with the use of driver gene mutations for diagnosis of myelofibrosis, non-driver gene mutations that affect its prognosis have also been identified, and new prognostic models based on them have been proposed. Furthermore, several important findings have been reported across diverse research fields, such as determining the appropriate modality for reducing splenomegaly before transplantation either by splenectomy or drug therapy, pre-transplant conditioning and donor selection, and long-term follow-up after transplantation. However, due to the relative rarity of myelofibrosis, it is difficult to keep up with the latest findings and develop the best clinical treatment regimens for patients. The purpose of this study is to summarize the current status and recent findings in transplantation therapy for myelofibrosis and to identify the challenges faced during treatment.